← Back to Search
Pleural Mesothelioma: Little Evidence, Still Time To Do Trials
T. Treasure, A. Sedrakyan
Published 2004 · Medicine
Download PDFAnalyze on Scholarcy
CONTEXT The incidence of malignant pleural mesothelioma is increasing throughout most of the world. This cancer is uniformly fatal, and characterised by progressive breathlessness and unremitting pain in the chest wall. From the onset of symptoms, survival is from a few weeks to a few years. Desperation by patients and doctors has driven a search for effective treatments. Clinical benefits are marginal and evidence of a good quality is lamentably lacking. STARTING POINT David Sugarbaker is the world's leading proponent of extrapleural pneumonectomy (EPP), an operation in which all the pleura is removed with the lung, pericardium, and diaphragm. He has recently reported the complications of this radical surgery in a series of 496 operations (J Thorac Cardiovasc Surg 2004; 128: 138-46). Although EPP as part of trimodality therapy (preoperative chemotherapy and postoperative radiation) is thought to be the best that can be offered and is regarded as the standard of care for selected patients given the morbidity associated with it, evidence for benefit is needed to justify its wider use. WHERE NEXT? With the increase in the number of cases there is increasing awareness of the disease, leading to earlier diagnosis, and an expectation that something must be done. Survival is short and the treatments on offer are onerous. The only responsible approach from a scientific, compassionate, or economic view (and why not combine all three?) is to find evidence of effectiveness to avoid futile and distressing treatment when possible.
This paper references
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure.
J. Hodgson (2000)
Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.
V. Rusch (1999)
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura--a single-institution experience with 189 patients.
L. de Graaf-Strukowska (1999)
A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma
S. Bydder (2004)
Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends
F. Montanaro (2004)
Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma
H. Pass (2006)
A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma.
J. Friedberg (2003)
Epidemiology of malignant mesothelioma in Australia.
A. Musk (2004)
Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.
D. Sugarbaker (1999)
The management of malignant pleural mesothelioma; single centre experience in 10 years.
T. Aziz (2002)
BTS randomised feasibility study of active symptom control with or without chemotherapy in malignant pleural mesothelioma: ISRCTN 54469112
M. Muers (2004)
Mesothelioma--VATS biopsy and lung mobilization improves diagnosis and palliation.
M. Grossebner (1999)
Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases.
F. Monetti (2004)
Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma.
T. T. Lee (2002)
The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma.
D. Stewart (2004)
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.
D. Sugarbaker (2004)
Survival in surgically diagnosed patients with malignant mesothelioma in current practice
C. Tan (2002)
Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma.
R. V. van Klaveren (2004)
The management of malignant pleural mesothelioma.
G. Maggi (2003)
Cytoreductive Surgery Combined With Intraoperative Hyperthermic Intrathoracic Chemotherapy for Stage I Malignant Pleural Mesothelioma
S. van Ruth (2003)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Asbestos and mesothelioma in South Africa.
R. Abratt (2004)
Promising Early Local Control of Malignant Pleural Mesothelioma Following Postoperative Intensity Modulated Radiotherapy (IMRT) to the Chest
A. Ahamad (2003)
Pleurodesis for malignant pleural effusions.
P. Shaw (2004)
Surgical treatment of malignant pleural mesothelioma: a review.
S. van Ruth (2003)
Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma.
A. Ahamad (2003)
Changing trends in US mesothelioma incidence
H. Weill (2004)
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma.
G. Ceresoli (2001)
Trimodality management of malignant pleural mesothelioma.
G. Maggi (2001)
The European mesothelioma epidemic
J. Peto (1999)
This paper is referenced by
Mesothelioma from the patient's perspective.
H. Clayson (2005)
A phase II study of intrapleural immuno-chemotherapy, pleurectomy/decortication, radiotherapy, systemic chemotherapy and long-term sub-cutaneous IL-2 in stage II-III malignant pleural mesothelioma.
M. Lucchi (2007)
Diagnostic biomarkers of malignant pleural mesothelioma
JoseAntonio Rodriguez Portal (2009)
Palliative intracavitary carboplatin therapy in a cat with suspected pleural mesothelioma
A. Sparkes (2005)
A Systematic Review of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
C. Cao (2010)
Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed
P. Bertino (2007)
BTS statement on malignant mesothelioma in the UK, 2007
Surgical Management of Mesothelioma
M. Kent (2006)
Ten traps for the unwary in surgical series: a case study in mesothelioma reports.
T. Treasure (2007)
Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
P. Borasio (2008)
Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools?
N. van Zandwijk (2012)
Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein.
J. Creaney (2005)
Scuola di Dottorato in Scienze Fisiopatologiche e neuropsicobiologiche e assistenziali del ciclo della vita - Ciclo XXVIII
Roberto Weinstein (2015)
Can ▼pemetrexed help in malignant mesothelioma?
Human malignant mesothelioma: molecular mechanisms of pathogenesis and progression.
E. P. Spugnini (2006)
Complexity of the intervention
P. Yudkin (2016)
Human neoplastic mesothelial cells express voltage-gated sodium channels involved in cell motility.
G. Fulgenzi (2006)
Doubt and its resolution in mesothelioma, pulmonary metastases and lung cancer
Tom Treasure (2012)
MDM2 is an important prognostic and predictive factor for platin–pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53
R. F. Walter (2015)
Management of malignant pleural effusions
R. Bennett (2005)
Kapitel 13 – Tumoren der Lunge und des Mediastinums
Joachim Preiss (2006)
Radical surgery for malignant pleural mesothelioma: results and prognosis.
M. Okada (2008)
BAP1 Protein is a Progression Factor in Malignant Pleural Mesothelioma
L. Arzt (2013)
A narrative review of current treatment strategies and emerging therapies in malignant pleural mesothelioma
Élise Di Lena (2020)
Multidisciplinary treatment of malignant pleural mesothelioma.
G. Ceresoli (2007)
Malignant Diseases Attributed to Asbestos Exposure
Gary D. Friedman (2011)
Malignant mesothelioma: Canadian perspective and research directions
C. Lee (2008)
Constrictive pericarditis after left extrapleural pneumonectomy and radiotherapy for malignant mesothelioma.
E. Hickey (2007)
Le mésothéliome pleural malin : incertitudes et espoirs face à une épidémie annoncée
J. Margery (2007)
Editorial Letter from President of the European Society for Cardiothoracic Surgery (EACTS)
T. Treasure (2006)
EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors
H. Kothmaier (2007)
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)See more